Shallow WGS of individual CTCs identifies actionable targets for informing treatment decisions in metastatic breast cancer
Open Access
- 10 September 2022
- journal article
- research article
- Published by Springer Nature in British Journal of Cancer
- Vol. 127 (10) , 1858-1864
Abstract
Background: We report copy-number profiling by low-pass WGS (LP-WGS) in individual circulating tumour cells (CTCs) for guiding treatment in patients with metastatic breast cancer (MBC), comparing CTC results with mutations detected in circulating tumour DNA (ctDNA) in the same blood samples. Methods: Across 10 patients with MBC who were progressing at the time of blood sampling and that had >20 CTCs detected by CellSearch®, 63 single cells (50 CTCs and 13 WBCs) and 16 cell pools (8 CTC pools and 8 WBC pools) were recovered from peripheral blood by CellSearch®/DEPArray™ and sequenced with Ampli1 LowPass technology (Menarini Silicon Biosystems). Copy-number aberrations were identified using the MSBiosuite software platform, and results were compared with mutations detected in matched plasma cfDNA analysed by targeted next-generation sequencing using the Oncomine™ Breast cfDNA Assay (Thermo Fisher). Results: LP-WGS data demonstrated copy-number gains/losses in individual CTCs in regions including FGFR1, JAK2 and CDK6 in five patients, ERBB2 amplification in two HER2-negative patients and BRCA loss in two patients. Seven of eight matched plasmas also had mutations in ctDNA in PIK3CA, TP53, ESR1 and KRAS genes with mutant allele frequencies (MAF) ranging from 0.05 to 33.11%. Combining results from paired CTCs and ctDNA, clinically actionable targets were identified in all ten patients. Conclusion: This combined analysis of CTCs and ctDNA may offer a new approach for monitoring of disease progression and to direct therapy in patients with advanced MBC, at a time when they are coming towards the end of other treatment options.Keywords
Funding Information
- Cancer Research UK (C14315/A13462X, C14315/A13462X, C14315/A13462X)
This publication has 36 references indexed in Scilit:
- Circulating Tumor Cells Predict Survival in Early Average-to-High Risk Breast Cancer PatientsJNCI: Journal of the National Cancer Institute, 2014
- Reproducible copy number variation patterns among single circulating tumor cells of lung cancer patientsProceedings of the National Academy of Sciences, 2013
- Activating ESR1 mutations in hormone-resistant metastatic breast cancerNature Genetics, 2013
- Personalized Oncology Through Integrative High-Throughput Sequencing: A Pilot StudyScience Translational Medicine, 2011
- GISTIC2.0 facilitates sensitive and confident localization of the targets of focal somatic copy-number alteration in human cancersGenome Biology, 2011
- Antiestrogens and Their Therapeutic Applications in Breast Cancer and Other DiseasesAnnual Review of Medicine, 2011
- Integrative genomics viewerNature Biotechnology, 2011
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)European Journal of Cancer, 2009
- Circulating Tumor Cells Predict Survival Benefit from Treatment in Metastatic Castration-Resistant Prostate CancerClinical Cancer Research, 2008
- Circulating Tumor Cells, Disease Progression, and Survival in Metastatic Breast CancerNew England Journal of Medicine, 2004